BALTIMORE, May 16, 2016 – Elixirgen has entered into a license agreement with the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH).
This sublicensable license agreement involves several patents that enable Elixirgen to develop, manufacture, and market research reagents that are based on the gene ZSCAN4. The reagents are used to treat pluripotent stem cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).
The technologies behind these patents were co-invented by Dr. Minoru Ko, Elixirgen’s co-founder and chief scientific officer, while he served as senior investigator and section chief at the Intramural Research Program, the internal research program of the NIH.
This license agreement fortifies Elixirgen’s existing patent portfolios regarding ZSCAN4, a gene in which Elixirgen specializes and which holds great therapeutic promise.
Elixirgen is a biopharmaceutical company located at the Science + Technology Park at Johns Hopkins. The company specializes in regenerative and rejuvenative medicine, currently developing therapies for chromosome abnormalities such as Down syndrome, telomere diseases, muscular dystrophies, and aging-associated diseases as well as treatments for cell rejuvenation. Elixirgen is focused on curing humanity’s ailments through stem cell biology.
About the National Institute on Aging:
The NIA leads the federal government effort conducting and supporting research on aging and the health and well-being of older people. The Institute’s broad scientific program seeks to understand the nature of aging and to extend the healthy, active years of life. For more information on research, aging, and health, go to www.nia.nih.gov.
About the National Institutes of Health (NIH):
NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.